{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:23:07Z","timestamp":1794576187506,"version":"4.9.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013791","name":"Bowel Cancer UK","doi-asserted-by":"publisher","award":["24PG0009"],"award-info":[{"award-number":["24PG0009"]}],"id":[{"id":"10.13039\/100013791","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009795","name":"Pancreatic Cancer UK","doi-asserted-by":"publisher","award":["EDG2023-24_Teif"],"award-info":[{"award-number":["EDG2023-24_Teif"]}],"id":[{"id":"10.13039\/100009795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jcyt.2026.102931","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:13:38Z","timestamp":1781136818000},"page":"102931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["MSC-delivered high-affinity variants of soluble PD1 lead to tumor regression"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8446-4779","authenticated-orcid":false,"given":"Serap","family":"Gokcen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2263-6163","authenticated-orcid":false,"given":"Tianyuan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5229-2123","authenticated-orcid":false,"given":"Phoebe Elizabeth","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6913-6676","authenticated-orcid":false,"given":"Natalia Magdalena","family":"Krajewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-4134","authenticated-orcid":false,"given":"Greg Nicholas","family":"Brooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-7558","authenticated-orcid":false,"given":"Stuart","family":"Rushworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0165-5354","authenticated-orcid":false,"given":"Philippe Pierre","family":"Laissue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf Michael","family":"Zwacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102931_bib0001","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102931_bib0002","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3390\/cancers17091408","article-title":"Advancing cancer treatment: a review of immune checkpoint inhibitors and combination strategies","volume":"17","author":"Mc Neil","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2026.102931_bib0003","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0004","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.jcyt.2026.102931_bib0005","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0006","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0007","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0008","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102931_bib0009","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2026.102931_bib0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12032-025-02822-1","article-title":"Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?","volume":"42","author":"Zamani","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0011","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0012","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0013","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jcyt.2026.102931_bib0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","article-title":"PD-1: an inhibitory immunoreceptor involved in peripheral tolerance","volume":"22","author":"Nishimura","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0016","first-page":"1037","article-title":"AP-1 transcription factors as regulators of immune responses in cancer","author":"Atsaves","year":"201911","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2026.102931_bib0017","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00262-021-02924-5","article-title":"Diacylglycerol kinase \u03b1 inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program","volume":"70","author":"Arranz-Nicol\u00e1s","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2026.102931_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf Open Immunol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0019","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","author":"Ghiotto","year":"2010","journal-title":"Int Immunol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0020","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3390\/ijms23105837","article-title":"PD-1\/PD-L1, MDSC pathways, and checkpoint inhibitor therapy in Ph(-) myeloproliferative neoplasm: a review","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2026.102931_bib0021","doi-asserted-by":"crossref","first-page":"8599","DOI":"10.3390\/ijms23158599","article-title":"Beyond cancer: regulation and function of pd-l1 in health and immune-related diseases","volume":"23","author":"Beenen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2026.102931_bib0022","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.4049\/jimmunol.169.7.3581","article-title":"B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis","volume":"169","author":"Mazanet","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0023","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1074-7613(00)80117-X","article-title":"B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha","volume":"11","author":"Swallow","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2026.102931_bib0024","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13062-025-00687-y","article-title":"Necroptosis-driven T cell activation promotes IL-6-mediated PD-L1 upregulation in cholangiocarcinoma cells: IL-6 gene signature as a biomarker for chemo-immunotherapy response","volume":"20","author":"Lomphithak","year":"2025","journal-title":"Biol Direct"},{"key":"10.1016\/j.jcyt.2026.102931_bib0025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2019.00847","article-title":"Human pancreatic carcinoma-associated fibroblasts promote expression of co-inhibitory markers on CD4(+) and CD8(+) T-cells","volume":"10","author":"Gorchs","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0026","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2026.102931_bib0027","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002627","article-title":"Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR","volume":"9","author":"Bayless","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102931_bib0029","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/stem.533","article-title":"Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells","volume":"28","author":"Mohr","year":"2010","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcyt.2026.102931_bib0030","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/cancers11040568","article-title":"MSC.sTRAIL has better efficacy than MSC.FL-TRAIL and in combination with AKTi blocks pro-metastatic cytokine production in prostate cancer cells","volume":"11","author":"Mohr","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2026.102931_bib0031","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.scr.2011.05.002","article-title":"Both human and mouse mesenchymal stem cells promote breast cancer metastasis","volume":"7","author":"Albarenque","year":"2011","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.jcyt.2026.102931_bib0032","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2021.06.017","article-title":"Fas-threshold signalling in MSCs promotes pancreatic cancer progression and metastasis","volume":"519","author":"Mohr","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jcyt.2026.102931_bib0033","first-page":"3603","article-title":"Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors","volume":"62","author":"Studeny","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102931_bib0034","doi-asserted-by":"crossref","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","article-title":"Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging","volume":"112","author":"Maute","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2026.102931_bib0035","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/art.27451","article-title":"Large-scale extraction and characterization of CD271+ multipotential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or minimally cultured multipotential stromal cells","volume":"62","author":"Jones","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jcyt.2026.102931_bib0036","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.4161\/15384047.2014.972183","article-title":"DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer","volume":"15","author":"Yu","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jcyt.2026.102931_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.19","article-title":"Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects","volume":"4","author":"Yu","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jcyt.2026.102931_bib0038","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1111\/j.1582-4934.2008.00317.x","article-title":"Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model","volume":"12","author":"Mohr","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0039","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2147\/OTT.S141040","article-title":"Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential","volume":"12","author":"Baldini","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jcyt.2026.102931_bib0040","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0041","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0042","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0043","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18440","article-title":"Durvalumab alone or combined with novel agents for unresectable stage III non-small cell lung cancer: update from the COAST randomized clinical trial","volume":"8","author":"Aggarwal","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jcyt.2026.102931_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1680838","article-title":"Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer\u2014a brief update","volume":"16","author":"Park","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0046","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ccell.2023.02.005","article-title":"Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment","volume":"41","author":"Klement","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2026.102931_bib0047","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1172\/JCI96113","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2026.102931_bib0048","doi-asserted-by":"crossref","first-page":"e01677","DOI":"10.1128\/JVI.01677-19","article-title":"Engineering newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines","volume":"94","author":"Vijayakumar","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0049","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.str.2016.06.026","article-title":"Structure and dynamics of PD-L1 and an ultra-high-affinity PD-1 receptor mutant","volume":"24","author":"Pascolutti","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.jcyt.2026.102931_bib0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jcyt.2026.102931_bib0051","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.canlet.2017.11.025","article-title":"The future of mesenchymal stem cell-based therapeutic approaches for cancer\u2014from cells to ghosts","volume":"414","author":"Mohr","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jcyt.2026.102931_bib0052","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1074\/jbc.M114.605063","article-title":"CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats","volume":"290","author":"Yang","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcyt.2026.102931_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2326-6066.CIR-14-0209","article-title":"Tumors: wounds that do not heal-redux","volume":"3","author":"Dvorak","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2026.102931_bib0054","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pharmthera.2019.04.005","article-title":"Mesenchymal stem cells: from regeneration to cancer","volume":"200","author":"Li","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jcyt.2026.102931_bib0055","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fcell.2020.00697","article-title":"Mesenchymal stem cells adaptively respond to environmental cues thereby improving granulation tissue formation and wound healing","volume":"8","author":"Jiang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0056","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8085637","article-title":"In vivo tracking of chemokine receptor CXCR4-engineered mesenchymal stem cell migration by optical molecular imaging","volume":"2017","author":"Kalimuthu","year":"2017","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.jcyt.2026.102931_bib0057","first-page":"97","article-title":"CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas","volume":"38","author":"Park","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0058","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.cgt.7700827","article-title":"Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors","volume":"12","author":"Sato","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102931_bib0059","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1757-2215-3-12","article-title":"Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor","volume":"3","author":"Komarova","year":"2010","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.jcyt.2026.102931_bib0060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s13287-020-01920-3","article-title":"Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application","volume":"11","author":"Lee","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102931_bib0061","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3727\/096368912X653246","article-title":"A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion","volume":"22","author":"Xinaris","year":"2013","journal-title":"Cell Transplant"},{"key":"10.1016\/j.jcyt.2026.102931_bib0062","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12645-023-00203-9","article-title":"Generation of magnetic biohybrid microrobots based on MSC.sTRAIL for targeted stem cell delivery and treatment of cancer","volume":"14","author":"Gundersen","year":"2023","journal-title":"Cancer Nanotechnol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0063","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/scd.2008.0253","article-title":"Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect","volume":"18","author":"Fischer","year":"2009","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.jcyt.2026.102931_bib0064","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","article-title":"Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6","volume":"5","author":"Lee","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102931_bib0065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13287-020-01770-z","article-title":"Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with (89)Zr-oxine PET-CT","volume":"11","author":"Patrick","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102931_bib0066","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/678063","article-title":"Biodistribution of mesenchymal stem\/stromal cells in a preclinical setting","volume":"2013","author":"Sensebe","year":"2013","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.jcyt.2026.102931_bib0067","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.TP.0000128334.93343.B3","article-title":"Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice","volume":"78","author":"Allers","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jcyt.2026.102931_bib0068","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/14653241003631815","article-title":"Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment","volume":"12","author":"Kidd","year":"2010","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102931_bib0069","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/cgt.2014.68","article-title":"Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma","volume":"22","author":"Lathrop","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102931_bib0070","doi-asserted-by":"crossref","first-page":"31319","DOI":"10.1073\/pnas.2019743117","article-title":"Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice","volume":"117","author":"Hu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2026.102931_bib0071","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00125-022-05708-3","article-title":"Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade","volume":"65","author":"Kawada-Horitani","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcyt.2026.102931_bib0072","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12935-025-03741-x","article-title":"Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword","volume":"25","author":"Kamrani","year":"2025","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jcyt.2026.102931_bib0073","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.stem.2013.09.006","article-title":"Mesenchymal stromal cells: sensors and switchers of inflammation","volume":"13","author":"Bernardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102931_bib0074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010088","article-title":"A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype","volume":"5","author":"Waterman","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102931_bib0075","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0076","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102931_bib0077","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102931_bib0078","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3389\/fimmu.2020.00922","article-title":"TNFSF14: LIGHTing the way for effective cancer immunotherapy","volume":"11","author":"Skeate","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102931_bib0079","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/jcmm.12839","article-title":"hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine","volume":"20","author":"Sabapathy","year":"2016","journal-title":"J Cell Mol Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:24:10Z","timestamp":1794572650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926008923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":79,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1465324926008923"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102931","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MSC-delivered high-affinity variants of soluble PD1 lead to tumor regression","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102931"}}